Bremer, Edwin <br/><br/>
Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.  [electronic resource] 

 -  Cancer research  Jan 2008 
 - 597-604 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-07-5171  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>B-Lymphocytes--drug effects<br/>CHO Cells<br/>Cricetinae<br/>Cricetulus<br/>Fas Ligand Protein--agonists<br/>Female<br/>Genetic Therapy--adverse effects<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--genetics<br/>Lymphoma, Non-Hodgkin--genetics<br/>Male<br/>Recombinant Fusion Proteins--adverse effects<br/>Rituximab<br/>Signal Transduction--drug effects<br/>Single-Chain Antibodies<br/>Tumor Cells, Cultured